Charles F. Wagner, Jr
2020
In 2020, Charles F. Wagner, Jr earned a total compensation of $6.1M as EVP & Chief Financial Officer at Vertex Pharmaceuticals, a 75% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $946,680 |
|---|---|
| Salary | $726,923 |
| Stock Awards | $4,375,585 |
| Other | $41,202 |
| Total | $6,090,390 |
Wagner received $4.4M in stock awards, accounting for 72% of the total pay in 2020.
Wagner also received $946.7K in non-equity incentive plan, $726.9K in salary and $41.2K in other compensation.
Rankings
In 2020, Charles F. Wagner, Jr's compensation ranked 1,707th out of 13,090 executives tracked by ExecPay. In other words, Wagner earned more than 87.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,707 out of 13,090 | 87th |
Division Manufacturing | 648 out of 5,617 | 89th |
Major group Chemicals And Allied Products | 232 out of 2,248 | 90th |
Industry group Drugs | 195 out of 1,948 | 90th |
Industry Pharmaceutical Preparations | 136 out of 1,453 | 91st |
Source: SEC filing on April 7, 2022.
Wagner's colleagues
We found three more compensation records of executives who worked with Charles F. Wagner, Jr at Vertex Pharmaceuticals in 2020.